2023.08.24
Monitor Corporation, a medical AI company led by CEO Lee Kyung-joon, announced on the 24th that its AI solution for early lung cancer diagnosis using CT scans has been designated as an "Outstanding R&D Innovation Product" by the Ministry of SMEs and Startups (MSS) for the first half of 2023.
This AI solution is the first in its field to receive Class 3 medical device approval from the Ministry of Food and Drug Safety and to be recognized as an innovation product for early lung cancer diagnosis, highlighting its technological excellence.
The Outstanding R&D Innovation Product designation identifies products developed through MSS R&D projects that demonstrate technological innovation, market potential, and societal need. The designation supports public procurement and offers various sales channel benefits, including direct public contracts and government pilot purchases.
CEO Lee Kyung-joon expressed pride in the recognition and noted that the AI solution, already recognized by major Korean university hospitals, is now poised to secure a broader distribution network.
See full article in Korean at getnews.co.kr